Holen Sie sich die Stockscreener-App
13.84
0.80%
0.11
Handel nachbörslich:
13.83
-0.010
-0.07%
Schlusskurs vom Vortag:
$13.73
Offen:
$13.76
24-Stunden-Volumen:
35.43M
Relative Volume:
7.32
Marktkapitalisierung:
$987.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-4.1939
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
+53.27%
1M Leistung:
+57.27%
6M Leistung:
+565.38%
1J Leistung:
+515.11%
1-Tages-Spanne:
$13.76
$13.85
1-Wochen-Bereich:
$7.08
$25.00
52-Wochen-Spanne:
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(760) 407-6511
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
13.84 | 979.75M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Eli Lilly Scoops Up Ventyx Biosciences in $1.2 Billion Acquisition - NAVLIN DAILY
Lilly’s Ventyx Buyout Will Swell Interest In NLRP3 inhibitors - Citeline News & Insights
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX) - MarketScreener
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - MedCity News
Lilly buys Ventyx in $1.2bn deal to tackle chronic inflammation - BioXconomy
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences - PharmExec.com
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Asianet Newsable
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1? - Yahoo Finance
Lilly to acquire Ventyx Biosciences stock for $14 per share - Investing.com
Lilly Agrees to Acquire Ventyx Biosciences - Contract Pharma
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next - TechStock²
Lilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal - European Pharmaceutical Review
Eli Lilly stock to acquire Ventyx for $1.2 billion, Cantor Fitzgerald maintains Overweight rating - Investing.com
Lilly announces acquisition of Ventyx Biosciences for around $1.2bn - PMLiVE
VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders - The Joplin Globe
Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts - TipRanks
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammatory Disease Portfolio - geneonline.com
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact - BioSpace
Lilly buys inflammation biotech Ventyx for $1.2B in wake of Parkinson's, CV readouts - Fierce Biotech
Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion - GuruFocus
Lilly confirms bid to acquire Ventyx Biosciences - The Pharma Letter
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn - Pharmaceutical Technology
Ventyx Biosciences jumps on report Eli Lilly nears more than $1B deal - MSN
Ventyx Biosciences downgraded to Hold from Buy at Canaccord - TipRanks
Ventyx Biosciences downgraded to Neutral from Buy at UBS - TipRanks
Lilly to acquire Ventyx Biosciences stock for $1.2 billion, Canaccord cuts rating - Investing.com Canada
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com Canada
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com
Lilly Commits $1.2B to Transform Oral Therapy Landscape with Ventyx Acquisition - geneonline.com
Lilly Inks $1.2bn Deal For Ventyx In Broader Pipeline Expansion - Citeline News & Insights
Significant price jump for US biotech company - medwatch.com
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - The Malaysian Reserve
Ventyx downgraded to Market Perform from Outperform at LifeSci Capital - TipRanks
Eli Lilly to Acquire Drug Developer Ventyx for $1.2 Billion, Expanding in Autoimmune Field - Bitget
Lilly to buy Ventyx Biosciences for $1.2 billion - Indian Pharma Post
Shareholder Alert: The Ademi Firm investigates whether Ventyx Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders - Morningstar
Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion, Expanding Inflammation Portfolio - NAI500
Confirming rumours, Lilly to buy Ventyx in $1.2B deal - FirstWord
Eli Lilly confirms plan to buy Ventyx Biosciences in $1.2 billion deal - MSN
Eli Lilly confirms deal to buy Ventyx Biosciences for $14 a share - MSN
Eli Lilly to buy Ventyx Biosciences for $1.2 billion - 104.1 WIKY
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion - GuruFocus
Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal - Investor's Business Daily
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14 - TechStock²
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Eli Lilly to buy Ventyx Biosciences for $1.2bn - MLex
Eli Lilly to Acquire Ventyx Biosciences in Cash Deal - TipRanks
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy - Bitget
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy By Reuters - Investing.com
Ventyx Biosciences Signs Multiple Material Agreements - TradingView — Track All Markets
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus - TechStock²
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):